Fort Worth, Texas-based emerging commercial stage company Wound Management Technologies, Inc. recently appointed orthopedic surgeon Blaine Farless as the new medical director of their Resorbable Orthopedic Products subsidiary (ROP). The company announced the nomination ahead of its plans to commercialize its primary product, Cellerate RX, a collagen product line, for the treatment of all wound types except 3rd degree burns, which has already been cleared by the U.S. Food and Drug Administration.
With 27 years of experience as a board-certified orthopedic surgeon, Blaine Farless is currently working at the Cleburne Orthopedic and Sports Medicine, as well as at the Texas Health Harris Methodist Hospital Cleburne and the Glen Rose Medical Center. “The resorbable hemostat products in development by the ROP subsidiary of Wound Management Technologies appears to offer ease of use and cost effectiveness in addition to not slowing bone growth and avoiding long term problems. I am thrilled at the opportunity to work with the company as we bring this product to market,” Farless stated.
Speaking about Wound Management Technologies’ Cellerate RX, Farless explained that bone bleeding during surgery has always been an issue, and that the only viable means of controlling it is the use of beeswax. Even though it is “adequate and easy to use,” beeswax prevents bone healing and created potential future problems. “Next generation products did not cause long term problems but were difficult to use in addition to being less effective and more costly,” he added.
In addition to the two facilities where he practices, Farless also holds staff privileges at three other hospitals in the Fort Worth region. With an undergraduate degree in Chemical Engineering and having completed his medical studies at the University of Texas Health Science Center in San Antonio, the surgeon is currently a member of the Academy of Orthopedic Surgeons, Texas Medical Association, Texas Orthopedic Association, and Texas Sports Medicine Association.
“We are excited to introduce Dr. Farless as our new Medical Director for ROP as he brings a wealth of knowledge in orthopedics in both the clinical as well as the surgical setting,” said the Chief Executive Officer of Wound Management Technologies, Robert Lutz, Jr. “Orthopedic surgery is a growth avenue for our resorb able hemostat products that are in the final stages of development. Dr. Farless is a champion of the clinical efficacy and cost-effectiveness that the product will bring to surgeries.”
In addition to the patented collagen product line CellerateRX, Wound Management Technologies is also currently working on the development of other advanced biotech products, namely a patented resorbable bone hemostat line, which is already in its late stages of development. Last year, the company was acquired by the Atlanta-based medical device company Brookhaven Medical, Inc., as a way of expanding both companies’ offerings.